Federico Bakal
Federico Bakal has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Berlin
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
1 shared publication - Claudio Martin
Thoracic Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina
1 shared publication - Claudio Vicente Sole
Instituto de Radiomedicina
1 shared publication - Cristina Carvalho Pacheco
Universidade Estadual da Paraíba (UEPB)
1 shared publication - Eduardo Cazap
Sociedad Latino Americana y del Caribe De Oncología Médica, RINC-SLACOM, Buenos Aires, Argentina
1 shared publication Erick Rocha
Department of Hematology and Oncology, Clinic of the Americas Santa Cruz, Bolivia Nº 5100 Beni Av, Santa Cruz, Bolivia
1 shared publication
Latest Publications
- Open Access
- 25 July 2023
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 95 (3)
Primary Bladder Sarcoma: A multi-institutional experience from the Rare Cancer Network
Purpose or Objective: Primary sarcoma of the urinary bladder (SUB) is a rare but aggressive form of bladder cancer (BCa). Available evidence on SUB is limited to case reports and small series. The aim of the present multi-institutional study was to assess the clinical features, treatments, and outcomes of patients with SUB. Materials and methods: Using a standardized database, 7 institutions retrospectively collected the demographics, risk factors, clinical presentation, treatment modalities and follow-up data on patients with SUB between January 1994 and September 2021. The main inclusion criteria included BCa with soft tissue tumor histology and sarcomatoid differentiation. Results: Fifty-three patients (38 men and 15 women) were identified. Median follow-up was 18 months (range 1-263 months). Median age at presentation was 69 years (range 16-89 years). Twenty-six percent of patients had a prior history of pelvic radiotherapy (RT), and 37% were previous smokers. The main presenting symptoms at diagnosis were hematuria (52%), pelvic pain (27%), and both hematuria and pelvic pain (10%). American Joint Committee on Cancer (AJCC) 8 th edition stage II, III and IV at diagnosis were 21%, 63% and 16%, respectively. Treatment modalities included surgery alone (45%), surgery plus neo- or adjuvant-chemotherapy (17%), surgery plus neo- or adjuvant-RT (11%), RT with concurrent chemotherapy (4%), neo-adjuvant chemotherapy plus surgery plus adjuvant RT (2%) and palliative treatment (21%). Rates of local and distant recurrences were 49% and 37%, respectively. Five-year overall survival and progression-free survival (PFS) were 66.5% and 37.6%, respectively. No statistically significant differences in PFS between the treatment modalities were observed. Conclusions: Primary SUB is a heterogeneous disease group, commonly presenting at advanced stages and exhibiting aggressive disease evolution. In contrast to urothelial carcinoma, the primary pattern of recurrence of SUB is local, suggesting the need for multimodal approaches. Continuous international collaborative efforts seem warranted to provide guidance on how to best tailor treatments based on SUB-specific indices.
- 25 July 2023
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 95 (3)
Open AccessPrimary Bladder Sarcoma: A multi-institutional experience from the Rare Cancer Network
Purpose or Objective: Primary sarcoma of the urinary bladder (SUB) is a rare but aggressive form of bladder cancer (BCa). Available evidence on SUB is limited to case reports and small series. The aim of the present multi-institutional study was to assess the clinical features, treatments, and outcomes of patients with SUB. Materials and methods: Using a standardized database, 7 institutions retrospectively collected the demographics, risk factors, clinical presentation, treatment modalities and follow-up data on patients with SUB between January 1994 and September 2021. The main inclusion criteria included BCa with soft tissue tumor histology and sarcomatoid differentiation. Results: Fifty-three patients (38 men and 15 women) were identified. Median follow-up was 18 months (range 1-263 months). Median age at presentation was 69 years (range 16-89 years). Twenty-six percent of patients had a prior history of pelvic radiotherapy (RT), and 37% were previous smokers. The main presenting symptoms at diagnosis were hematuria (52%), pelvic pain (27%), and both hematuria and pelvic pain (10%). American Joint Committee on Cancer (AJCC) 8 th edition stage II, III and IV at diagnosis were 21%, 63% and 16%, respectively. Treatment modalities included surgery alone (45%), surgery plus neo- or adjuvant-chemotherapy (17%), surgery plus neo- or adjuvant-RT (11%), RT with concurrent chemotherapy (4%), neo-adjuvant chemotherapy plus surgery plus adjuvant RT (2%) and palliative treatment (21%). Rates of local and distant recurrences were 49% and 37%, respectively. Five-year overall survival and progression-free survival (PFS) were 66.5% and 37.6%, respectively. No statistically significant differences in PFS between the treatment modalities were observed. Conclusions: Primary SUB is a heterogeneous disease group, commonly presenting at advanced stages and exhibiting aggressive disease evolution. In contrast to urothelial carcinoma, the primary pattern of recurrence of SUB is local, suggesting the need for multimodal approaches. Continuous international collaborative efforts seem warranted to provide guidance on how to best tailor treatments based on SUB-specific indices.
- Open Access
- 4 August 2022
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 16, 1436
Highlights of the ‘I Congress ecancer Choosing Wisely’ March 30 and 31, 2022 Santa Cruz, Bolivia
Highlights of the ‘I Congress ecancer Choosing Wisely’ March 30 and 31, 2022 Santa Cruz, Bolivia Ronald Limón1,2,3,4, Lucia Reynolds2,3,4, Erick Rocha2, Luci
- 4 August 2022
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 16, 1436
Open AccessHighlights of the ‘I Congress ecancer Choosing Wisely’ March 30 and 31, 2022 Santa Cruz, Bolivia
Highlights of the ‘I Congress ecancer Choosing Wisely’ March 30 and 31, 2022 Santa Cruz, Bolivia Ronald Limón1,2,3,4, Lucia Reynolds2,3,4, Erick Rocha2, Luci